What are the treatment recommendations for enteroinvasive E. coli (EIEC)? Should antimicrobials be used for treatment?

Comment by InpharmD Researcher

Current clinical practice guidelines from the Centers for Disease Control and Prevention (CDC) on traveler’s diarrhea and infectious diarrhea recommend that enteroinvasive E. coli (EIEC) cases initially be managed with supportive/symptomatic care, as most cases are acute and self-limiting. For persistent symptoms (>14-day duration), antibiotic treatment is indicated, with azithromycin or a fluoroquinolone recommended for EIEC; ciprofloxacin is the preferred fluoroquinolone given its narrower spectrum. Rifaximin represents another potential treatment option. Guidelines also explicitly recommend exclusion of enterohemorrhagic E. coli infection, as antimicrobial treatment can increase the likelihood of developing hemolytic uremic syndrome. Despite these recommendations, a comprehensive literature search did not identify any randomized, controlled studies on antimicrobial or other management strategies for EIEC; available primary literature was limited to a pediatric case report (Table 1).
Background

A 2025 Yellow Book chapter on post-travel diarrhea issued by the Centers for Disease Control and Prevention (CDC) provides guidance for evaluating international travelers who present with diarrhea after travel. Most cases of travelers’ diarrhea (TD) are acute and self-limiting and secondary to infectious pathogens, but some patients do develop persistent symptoms (>14-day duration). Persistent diarrhea symptoms are classified as either ongoing infection or coinfection with a second organism not targeted by initial therapy, previously undiagnosed gastrointestinal (GI) disease unmasked by the enteric infection, or post-infectious phenomena. Pathogen-specific antimicrobial management is recommended for most pathogens. Azithromycin or a fluoroquinolone is recommended for Shigella/enteroinvasive E. coli (EIEC), while explicit avoidance of antimicrobials is recommended for enterohemorrhagic E. coli (EHEC)/Shiga toxin-producing E. coli (STEC) given the risk for hemolytic uremic syndrome. For protozoal cases, including Giardia, Cyclospora, and Entamoeba histolytica, either nitazoxanide, trimethoprim-sulfamethoxazole, or a nitroimidazole is recommended. For EIEC, ciprofloxacin is slightly preferred over other fluoroquinolones given its narrower spectrum. The chapter notes that mucosal-inflammatory bacterial pathogens, including Shigella spp. and diarrheagenic E. coli, can occasionally produce persistent (>14-day) diarrhea, sometimes involving antibiotic-resistant organisms. Additionally, given the emergence of extensively drug-resistant strains, patients with severe disease (e.g., those with bacteremia or hospitalized) or immunocompromised status should receive empiric carbapenem therapy while awaiting susceptibility results. [1]

The 2024 CDC clinician guidance document on E. coli infection addresses EIEC as part of its broader category of diarrheagenic E. coli other than Shigella spp./STEC. For diarrheagenic E. coli, the panel suggests symptomatic management of most infections given their commonly self-limited nature, prioritizing rehydration therapy in patients with profuse diarrhea and/or vomiting. For cases requiring antimicrobial therapy, fluoroquinolones (such as ciprofloxacin), macrolides (such as azithromycin), and rifaximin are potential options. The panel additionally cautions clinicians that rising worldwide antimicrobial resistance rates mean that treatment decisions should weigh illness severity, likelihood of infection due to a drug-resistant pathogen, and adverse effects (including rash, antibiotic-associated colitis, and vaginal yeast infection). Antimotility agents are explicitly discouraged for patients with bloody diarrhea; the panel additionally recommends ruling out EHEC/STEC in patients with bloody diarrhea since antimicrobial treatment in these cases increases the risk of hemolytic uremic syndrome. [2]

The 2017 Infectious Disease Society of America (IDSA) guidelines for diagnosis and management of infectious diarrhea acknowledges EIEC as a pathogen associated with travel to resource-challenged countries, along with enteroaggregative and enterotoxigenic E. coli. Diagnosis of EIEC with stool testing requires either specialized culture, molecular assays, or nucleic acid amplification testing (NAAT) and not standard stool culturing; this is essential to rule out STEC, including the O157-H7 strain. Beyond this, the guideline does not provide treatment recommendations specific to EIEC in its organism-/pathogen-specific treatments. [3]

The 2017 graded expert panel report on prevention and treatment of TD critically appraised available literature on antibiotic and non-antibiotic prophylaxis and treatment, utility of available diagnostics, impact of multi-drug resistant (MDR) colonization, and the impact of the GI microbiome. EIEC is grouped with other invasive dysentery-causing organisms, including Shigella, Campylobacter, Aeromonas, Plesiomonas, and Yersinia enterocolitica. Antibiotics are recommended to treat severe TD (strong recommendation, high level of evidence). For cases of severe dysentery, azithromycin is the preferred first-line treatment (strong recommendation, high level of evidence), as well as acute watery diarrhea with greater than mild fevers. This recommendation is based on the greater likelihood of fluoroquinolone-resistant Campylobacter and other invasive causative pathogens. One referenced study in Thailand found azithromycin 1 gram as a single dose or 500 mg daily for 3 days as superior to levofloxacin 500 mg daily for 3 days. Fluoquinolones and rifaximin are given weak recommendations for severe non-dysenteric TD cases (weak recommendation, moderate level of evidence), and rifaximin is not recommended when EIEC is suspected. Additionally, single-dose antibiotic regimens may be used to treat moderate or severe TD (strong recommendation, high level of evidence). [4]

Background References: [1] Centers for Disease Control and Prevention: Yellow Book. Post-Travel Diarrhea. Published April 23, 2025. Accessed August 10, 2026. https://www.cdc.gov/yellow-book/hcp/post-travel-evaluation/post-travel-diarrhea.html
[2] Centers for Disease Control and Prevention: E. coli Infection (Escherichia coli). Information for Clinicians. Published May 14, 2024. https://www.cdc.gov/ecoli/hcp/guidance/index.html
[3] Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017;65(12):e45-e80. doi:10.1093/cid/cix669
[4] Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report. J Travel Med. 2017;24(suppl_1):S57-S74. doi:10.1093/jtm/tax026
Literature Review

A search of the published medical literature revealed 1 study investigating the researchable question:

What are the treatment recommendations for enteroinvasive E. coli (EIEC)? Should antimicrobials be used for treatment?

Level of evidence

D - Case reports or unreliable data  Read more→


Please see Table 1 for your response.

 

Enteroinvasive Escherichia coli severe dysentery complicated by rotavirus gastroenteritis

Design

 Case report

Case presentation

A 4-month-old malnourished male infant from a rural indigenous community in Tabasco, Mexico, presented with severe dysentery complicated by rotavirus gastroenteritis and enteroinvasive Escherichia coli (EIEC) infection. The infant exhibited signs of hypovolemic shock, severe dehydration, metabolic acidosis, and profound anemia upon admission, with clinical features including frequent watery stools progressing to bloody diarrhea, fever, and respiratory distress. Laboratory evaluation confirmed leukocytosis, thrombocytosis, low hemoglobin, and electrolyte disturbances, while stool analysis identified rotavirus and cultured E. coli isolates, one of which was molecularly confirmed as EIEC via polymerase chain reaction (PCR) targeting pathogenic E. coli genes. Other common enteric pathogens and parasites were excluded.

Initial management involved intravenous rehydration, broad-spectrum antibiotics (ampicillin 200 mg/kg/day, amikacin 7.5 mg/kg/day), and multiple blood transfusions necessitated by ongoing hemorrhagic colitis. The patient received intravenous fluids for 7 days and antibiotic treatment for 10 days. Despite the severity of gastrointestinal bleeding and systemic symptoms, the infant gradually improved, with resolution of fever and dysentery over two weeks, culminating in discharge with clinical recovery on hospital day 13. 

Study Author Conclusions

The report emphasizes the rarity of severe, life-threatening dysentery caused by EIEC in infants and highlights the diagnostic challenge due to the pathogen’s under-recognition in routine clinical laboratories.

The co-infection with rotavirus likely exacerbated disease severity by increasing intestinal permeability and facilitating invasive bacterial infection, as supported by prior in vitro and clinical evidence demonstrating rotavirus-enhanced enteric pathogen invasiveness. This case underscores the importance of comprehensive etiological identification in pediatric diarrheal illnesses, particularly in malnourished infants from resource-limited settings, to guide targeted therapy and improve outcomes.
Table 1 References:
[5] Pacheco-Gil L, Ochoa TJ, Flores-Romo L, DuPont HL, Estrada-Garcia T. Enteroinvasive Escherichia coli severe dysentery complicated by rotavirus gastroenteritis. J Infect. 2006;53(5):e211-e213. doi:10.1016/j.jinf.2006.01.021